Pfizer mission and vision statements are an indication of the potential a company can gain from uniquely crafted corporate statements. Ever since its foundation in 1849 by Charles Pfizer and Charles Erhart, the company has grown against all odds to become a leading pharmaceutical icon. In fact, it has received numerous top accreditations for its fortitude to shape positive changes in the pharmaceutical sector.
All these achievements comes down to its mission and vision statements. A corporate vision statement presents the future business ambitions of a company. In this case, Pfizer vision clearly states the impact the company desires to have on the care of its patients. The corporate mission statement directly relates to this concept. It outlines the strategies a company would exploit to achieve its vision together with its expectations.
In a summative approach, Pfizer conceptualizes the steps it would take to grow itself as the most valued firm of its kind. It is critical to note that the continued progress in the mission and vision of this company has been supported by the company’s core values.
Core values are the moralities that ensure the company remains streamlined towards its set goals and objectives. In the case of Pfizer, its values including customer focus, leadership, quality innovation, collaboration, respect for people, and performance among others have kept the company solid and progressive. Essentially, the manner in which these components work together reflects the dominance of Pfizer.
Pfizer mission statement is “to become the world’s most valued company to all of these people.” It zeroes down on the achievements that the company desires while at the same time meeting the expectations of all its patients. The following components can be associated with this mission statement:
- Simplifying healthcare
- Improving lives and communities
- Exceeding expectations
In the first component of its mission statement, Pfizer emphasizes the commitment of the company to create products that address the existing conditions more effectively. The company has demonstrated its trueness to this component through its innovative medicines despite scientific challenges in bringing such products for its patients.
In fact, the firm echoes its primary role that agrees with the needs of this component as being driven to discover the cure. The second component of Pfizer mission statement relates to the first one in the way the medical innovations of the company improves the quality of life of people by curing their conditions. Pfizer has gained recognition through its progressive medical products that have produced ‘miracle’ curative outcomes leaving a mark in the lives of people it touches.
By creating products that address even the most resistant diseases, Pfizer makes significant steps in the achievement of the third component of its mission statement. The company also extends its reach to other corporate responsibilities as shown in its outreach programs.
Pfizer vision statement is “Innovate to bring therapies to patients that significantly improve their lives.” It places an emphasis on the innovation principle as the driving force towards impacting a change in its clients. Some of the elements that relate to this vision statement include:
- Benefits to patients
Pfizer focusses on creating medicines and medical products. In fact, being the leader in the synthesis of the most sought after pharmaceutical products remains the top ambition of the company especially as shown in its product pipeline section. While doing so, the company echoes its commitment to providing products that directly benefit the patients. In this way, Pfizer reveals that its primary concern is to the patients while the rest come second.
Pfizer core values include “customer focus, leadership, quality innovation, collaboration, respect for people, integrity, and performance.” The following components make up the values of the company.
- Customer focus
- Quality innovation
- Respect for people
Pfizer first element of its core values reflects the primary beneficiary of all its efforts, and it closely echoes the desire of the company to lead the rest in the satisfaction of this expectation as part of its second component.
The company acknowledges it can only do this through innovations while at the same time collaborating and respecting other stakeholders as shown in its third and fourth components of its values. The company also understands that, by acting right at all the time, this will eventually be reflected in its quality performance in the pharmaceutical niche.
Al-Shaqha, W. M., & Zairi, M. (2000). Re-engineering pharmaceutical care: towards a patient-focused care approach. International journal of health care quality assurance, 13(5), 208-217.
Angaran, D. M. (1991). Quality assurance to quality improvement: measuring and monitoring pharmaceutical care. American journal of hospital pharmacy, 48(9), 1901-1907.
Chalmers, R. K., Adler, D. S., Haddad, A. M., Hoffman, S., Johnson, K. A., & Woodard, J. M. (1995). The essential linkage of professional socialization and pharmaceutical care. American Journal of Pharmaceutical Education, 59(1), 85-90.
Gitlow, H. S., & Melby, M. J. (1991). Framework for continuous quality improvement in the provision of pharmaceutical care. American journal of hospital pharmacy, 48(9), 1917-1925.
HAYASHI, S. I., Hayase, T., Mochizuki, M., Hashiguchi, M., & Takeuchi, K. (2005). Classification of pharmaceutical services from the viewpoint of patient satisfaction/dissatisfaction. Yakugaku zasshi, 125(1), 159-168.
Hirota, S., Kubo, K., Miyajima, H., Hong, P., & Won Park, Y. (2010). Corporate mission, corporate policies and business outcomes: evidence from Japan. Management decision, 48(7), 1134-1153.
Ingenhoff, D., & Fuhrer, T. (2010). Positioning and differentiation by using brand personality attributes: Do mission and vision statements contribute to building a unique corporate identity?. Corporate Communications: An International Journal, 15(1), 83-101.
Olutayo Otubanjo, B., & Melewar, T. C. (2007). Understanding the meaning of corporate identity: a conceptual and semiological approach. Corporate Communications: An International Journal, 12(4), 414-432.
Perrier, D. G., Winslade, N., Pugsley, J., Lavak, L., & Strand, L. M. (1995). Designing a pharmaceutical care curriculum. American Journal of Pharmaceutical Education, 59(2), 113-124.
Schneider, J. L., Wilson, A., & Rosenbeck, J. M. (2010). Pharmaceutical companies and sustainability: an analysis of corporate reporting. Benchmarking: An International Journal, 17(3), 421-434.
Schünemann, H. J., Woodhead, M., Anzueto, A., Buist, S., MacNee, W., Rabe, K. F., & Heffner, J. (2009). A vision statement on guideline development for respiratory disease: the example of COPD. The Lancet, 373(9665), 774-779. Sones, M., Grantham, S., & Vieira, E. T. (2009). Communicating CSR via pharmaceutical company web sites: Evaluating message frameworks for external and internal stakeholders. Corporate Communications: An International Journal, 14(2), 144-157.